A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency

Nobelpharma1 site in 1 country57 target enrollmentJanuary 2015

Overview

Phase: Phase 3
Intervention: NPC-02
Conditions: Zinc Deficiency
Sponsor: Nobelpharma
Enrollment: 57
Locations: 1
Primary Endpoint: The change amount of serum zinc concentration between starting and 8 weeks after dosing
Status: Completed
Last Updated: 7 years ago

The objective of this study is to evaluate efficacy and safety of NPC-02 in patients with Zinc Deficiency.

Registry

clinicaltrials.gov

Start Date

January 2015

End Date

November 2015

Last Updated

7 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Sponsor

Nobelpharma

Responsible Party

Sponsor

•Heavy hepatitis
•Malignant tumor
•Severe heart disease, hematological disorder, kidney disease and pancreatic disease, etc.
•The serum albumin under 2.8 g/dL
•Patient of allergy and hyperesthesia to zinc containing medicine manufacturing (including supplement)
•Patient who was taking a medicine including the zinc (including supplement) within 12 weeks before registration
•Pregnant, suspected pregnant, lactating, patients who wish to have a child
•Patient who participated in other clinical trials within 12 weeks before registration
•Unsuitable as a target of this clinical trial judged by doctor